Leveraging Unique mRNA and VLP Immunization Techniques
Featuring High-throughput Clone Screening
Achieving Improved Clone Survival Rate with Minimal Loss of Diversity
Multi-pass membrane proteins, intricately traversing the lipid bilayer of cell membranes multiple times, have emerged as invaluable therapeutic targets in the oncology sphere. Categorized into several families such as G protein-coupled receptors (GPCRs), ion channels, and transporters based on their functions, their antibody discovery poses unique challenges. These hurdles encompass intricate antigen preparation, the low rate of positive clone generation, and complexities in obtaining functional leads.
At ProBio, we have tailored an innovative solution to conquer these challenges in the quest for multi-pass membrane target therapeutics. Our unique approach combines mRNA and VLP immunization strategies, along with our state-of-the-art Powerdoma™ Hybridoma Discovery Platform. Enhanced with GPCR bioassay and an adept in vivo pharmacology platform, we deftly tackle these challenges head-on. As a result, we accelerate the procurement of antibody leads, ensuring functionality and developability, and bringing you one step closer to your discovery goals.
Multi-pass Membrane Antibody Expertise
Unique Techniques & Innovative Platform
GPCR Bioassay Platform